237 related articles for article (PubMed ID: 31117066)
21. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
23. Early Outcomes in Children With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Morishita KA; Moorthy LN; Lubieniecka JM; Twilt M; Yeung RSM; Toth MB; Shenoi S; Ristic G; Nielsen SM; Luqmani RA; Li SC; Lee T; Lawson EF; Kostik MM; Klein-Gitelman M; Huber AM; Hersh AO; Foell D; Elder ME; Eberhard BA; Dancey P; Charuvanij S; Benseler SM; Cabral DA;
Arthritis Rheumatol; 2017 Jul; 69(7):1470-1479. PubMed ID: 28371513
[TBL] [Abstract][Full Text] [Related]
24. Pauci-immune glomerulonephritis: does negativity of anti-neutrophilic cytoplasmic antibodies matters?
Sharma A; Nada R; Naidu GS; Minz RW; Kohli HS; Sakhuja V; Gupta KL; Rathi M
Int J Rheum Dis; 2016 Jan; 19(1):74-81. PubMed ID: 26269223
[TBL] [Abstract][Full Text] [Related]
25. Glomerular C3d as a novel prognostic marker for renal vasculitis.
Villacorta J; Diaz-Crespo F; Acevedo M; Guerrero C; Campos-Martin Y; García-Díaz E; Mollejo M; Fernandez-Juarez G
Hum Pathol; 2016 Oct; 56():31-9. PubMed ID: 27257040
[TBL] [Abstract][Full Text] [Related]
26. Effects of cyclophosphamide on the prognosis of Japanese patients with renal vasculitis associated with anti-neutrophil cytoplasmic antibody-positive microscopic polyangiitis.
Iwabuchi M; Nakaya I; Tsuchiya Y; Shibagaki Y; Yamaguchi T; Fukuhara S; Oe Y; Sakuma T; Sato T; Taguma Y; Soma J
Clin Exp Nephrol; 2016 Oct; 20(5):712-719. PubMed ID: 26590052
[TBL] [Abstract][Full Text] [Related]
27. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.
Karras A; Pagnoux C; Haubitz M; Groot K; Puechal X; Tervaert JWC; Segelmark M; Guillevin L; Jayne D;
Ann Rheum Dis; 2017 Oct; 76(10):1662-1668. PubMed ID: 28546260
[TBL] [Abstract][Full Text] [Related]
28. ANCA comes of age-but with caveats.
Hamour SM; Salama AD
Kidney Int; 2011 Apr; 79(7):699-701. PubMed ID: 21403654
[TBL] [Abstract][Full Text] [Related]
29. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
30. Tubulointerstitial damage and interstitial immune cell phenotypes are useful predictors for renal survival and relapse in antineutrophil cytoplasmic antibody-associated vasculitis.
Bitton L; Vandenbussche C; Wayolle N; Gibier JB; Cordonnier C; Verine J; Humez S; Bataille P; Lenain R; Ramdane N; Azar R; Mac Namara E; Hatron PY; Maurage CA; Perrais M; Frimat M; Vanhille P; Glowacki F; Buob D; Copin MC; Quéméneur T; Gnemmi V
J Nephrol; 2020 Aug; 33(4):771-781. PubMed ID: 31916228
[TBL] [Abstract][Full Text] [Related]
31. Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Acute Kidney Injury: Short-Term Recovery Predicts Long-Term Outcome.
Huang X; Chen L; Lan L; Ren P; Ni A; Ma Y; Wang Y; Zhu Y; Xu Y; Chen J; Han F
Front Immunol; 2021; 12():641655. PubMed ID: 34305886
[TBL] [Abstract][Full Text] [Related]
32. ANCA-associated vasculitis in scleroderma: A renal perspective
.
Kant S; Shah AA; Hummers LK; Wigley FM; Geetha D
Clin Nephrol; 2018 Dec; 90(6):413-418. PubMed ID: 30106367
[TBL] [Abstract][Full Text] [Related]
33. Treatment Outcomes of Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Patients Over Age 75 Years: A Meta-Analysis.
Morris AD; Elsayed ME; Ponnusamy A; Rowbottom A; Martin F; Geetha D; Dhaygude AP
Am J Nephrol; 2020; 51(4):327-336. PubMed ID: 32160625
[TBL] [Abstract][Full Text] [Related]
34. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.
McGregor JG; Hogan SL; Kotzen ES; Poulton CJ; Hu Y; Negrete-Lopez R; Kidd JM; Katsanos SL; Bunch DO; Nachman PH; Falk RJ
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1(Suppl 1):i123-31. PubMed ID: 25805743
[TBL] [Abstract][Full Text] [Related]
35. Renal Involvement in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Zonozi R; Niles JL; Cortazar FB
Rheum Dis Clin North Am; 2018 Nov; 44(4):525-543. PubMed ID: 30274621
[TBL] [Abstract][Full Text] [Related]
36. Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis.
Nasr SH; Said SM; Valeri AM; Stokes MB; Masani NN; D'Agati VD; Markowitz GS
Clin J Am Soc Nephrol; 2009 Feb; 4(2):299-308. PubMed ID: 19158367
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic characteristics and outcomes of renal thrombotic microangiopathy in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis.
Chen SF; Wang H; Huang YM; Li ZY; Wang SX; Yu F; Zhao MH; Chen M
Clin J Am Soc Nephrol; 2015 May; 10(5):750-8. PubMed ID: 25749534
[TBL] [Abstract][Full Text] [Related]
38. Experience with seven Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with remission-induction therapy with intravenous cyclophosphamide according to the CYCLOPS protocol.
Oiwa H; Yamasaki S; Endo K; Nojima T; Kumagai K; Sugiyama E
Intern Med; 2014; 53(20):2291-6. PubMed ID: 25318790
[TBL] [Abstract][Full Text] [Related]
39. The risk factors for early mortality and end-stage renal disease in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis: experiences from a single center.
Ni A; Chen L; Huang X; Ma Y; Lan L; Ren P; Wang Y; Zhu Y; Xu Y; Chen J; Han F
Clin Exp Med; 2021 Aug; 21(3):389-397. PubMed ID: 33768341
[TBL] [Abstract][Full Text] [Related]
40. Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease.
Rhee RL; Hogan SL; Poulton CJ; McGregor JA; Landis JR; Falk RJ; Merkel PA
Arthritis Rheumatol; 2016 Jul; 68(7):1711-20. PubMed ID: 26814428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
